Median progression-free survival was significantly longer in the panobinostat group than in the placebo group ( @ months -LSB- @ % CI @-@ -RSB- vs @ months -LSB- @-@ -RSB- ; hazard ratio -LSB- HR -RSB- @ , @ % CI @-@ ; p < @ ) .